Premium
Protective effect of albuterol delivered via a spacer device (Babyhaler®) against methacholine induced bronchoconstriction in young wheezy children
Author(s) -
Avital Avraham,
Godfrey Simon,
Schachter Jacob,
Springer Chaim
Publication year - 1994
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950170503
Subject(s) - medicine , methacholine , bronchoconstriction , inhaler , salbutamol , anesthesia , bronchodilator , bronchospasm , placebo , metered dose inhaler , asthma , auscultation , respiratory disease , lung , airway , alternative medicine , pathology
Nine young asthmatic children aged 2–5 years underwent methacholine challenge after placebo or albuterol administered by metered dose inhaler through a spacer device (Babyhalere®)* with a face mask in a double‐blind, cross‐over, randomized study. The methacholine challenge was performed using chest auscultation to define the provocative concentration of methacholine that causes wheezing (PCW). The PCW increased from a geometric mean of 0.28 mg/mL after placebo to 3.59 mg/mL after albuterol ( P < 0.0001). The protective effect of albuterol against methacholine‐induced bronchospasm was 3.7 ± 1.2 doubling doses. We conclude that administration of drugs from a metered dose inhaler through the Babyhaler® with a face mask is effective. Albuterol causes a major reduction in the bronchial hyperreactivity in young wheezy children shortly after administration. Pediatr Pulmonol. 1994; 17:281–284. © 1994 Wiley‐Liss, Inc.